Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Optimizing Mass Spectrometry Methods to Uncover M. tuberculosis Biomarkers in Extracellular Vesicles

ABSTRACT: Individuals exposed to Mtb can experience a range of outcomes: early bacterial clearance, latent Mtb infection (LTBI), asymptomatic TB (bacteriologically confirmed or not), or symptomatic TB (bacteriologically confirmed or clinically diagnosed). Current tools cannot reliably predict or distinguish these stages. Previous studies have identified Mtb peptides in extracellular vesicles (EVs) from TB patients’ serum, highlighting their potential as biomarkers. We aimed to identify Mtb proteins and peptides in serum EVs as potential biomarkers across TB stages, with a focus on differentiating asymptomatic individuals. We evaluated multiple mass spectrometry approaches, including optimizing the liquid chromatography gradient (more hydrophobic), and iteratively removed dominant peptides, to identify and differentially quantify Mtb peptides. We analyzed serum samples from healthy, HIV-negative South African adult volunteers enrolled in a TB risk study. Samples were categorized as prevalent TB (diagnosed within 30 days of baseline), incident TB (collected at baseline from participants who later developed TB), activated TB (collected at diagnosis, during follow-up, from incident cases), or controls (collected at baseline from participants who did not develop TB within the 15 months of the study).

INSTRUMENT(S):

ORGANISM(S): Mycobacterium Tuberculosis H37rv

TISSUE(S): Blood Serum

SUBMITTER: Luisa Nieto Ramirez

LAB HEAD: Karen Dobos

PROVIDER: PXD068329 | Pride | 2026-03-03

REPOSITORIES: Pride

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	KS-3658-MC-new-DDA.pdResult	Other
	KS-3658-MC-newEL500.pdResult	Other
	KS-3658-MC_newEL362.pdResult	Other
	KS3658-DDA-MC-HF_Gradient.pdResult	Other
	KS3658DDAMCHF_Gradient.mzTab	Mztab

Items per page:

1 - 5 of 21

Similar Datasets

Optimizing Mass Spectrometry Methods to Uncover M. tuberculosis Biomarkers in Extracellular Vesicles

Project description:Individuals exposed to Mtb can experience a range of outcomes: early bacterial clearance, latent Mtb infection (LTBI), asymptomatic TB (bacteriologically confirmed or not), or symptomatic TB (bacteriologically confirmed or clinically diagnosed). Current tools cannot reliably predict or distinguish these stages. Previous studies have identified Mtb peptides in extracellular vesicles (EVs) from TB patients’ serum, highlighting their potential as biomarkers. We aimed to identify Mtb proteins and peptides in serum EVs as potential biomarkers across TB stages, with a focus on differentiating asymptomatic individuals. We evaluated data-independent acquisition (DIA) mass spectrometry with different data analysis strategies to identify and differentially quantify Mtb peptides. We analyzed serum samples from healthy, HIV-negative South African adult volunteers enrolled in a TB risk study. Samples were categorized as prevalent TB (diagnosed within 30 days of baseline), incident TB (collected at baseline from participants who later developed TB), activated TB (collected at diagnosis, during follow-up, from incident cases), or controls (collected at baseline from participants who did not develop TB within the 15 months of the study).

2026-03-03 | PXD068197 | Pride

Optimizing Mass Spectrometry Methods to Uncover M. tuberculosis Biomarkers in Extracellular Vesicles

2026-03-03 | PXD068195 | Pride

Blood transcriptional signatures of asymptomatic FDG-PET/CT-defined Subclinical TB lesions and their prediction of future TB progression

Project description:Diagnostic tests for tuberculosis (TB) infection poorly predict future incident disease risk. We investigated a cohort of asymptomatic HIV-uninfected household contacts of TB in South Africa in which baseline lung lesions indicative of Subclinical TB identified by [18F]-fluoro-2-deoxy-D-glucose (FDG)-positron emission/computed tomography (PET/CT) had high predictive value for future TB over 5 years. RNA-sequencing analysis of whole blood samples at baseline PET/CT, 5-15m PET/CT2, and the TB diagnosis of incident TB revealed persistent enrichment of neutrophil and monocyte transcriptional modules in those with Subclinical TB and worsening and discrete lung abnormalities, while expression of a core set of type I IFN genes related to FDG-avid lymph nodes. Leveraging multiple machine learning algorithms, we derived gene signatures of various PET/CT lesion Subclinical phenotypesTB, future lesion worsening and TB diagnosis. prevalent and incident TB. Validating signatures in two independent cohorts against TB progression within 6,12,18 and fup to 24-29-months, confirmed gave AUC of 0.75-0.95 and 0.77-0.87 with performance above optimal sensitivity and wminimum specificity for the WHO target product profile for TB progression.

2025-08-09 | GSE240463 | GEO

Blood transcriptional signatures of asymptomatic FDG-PET/CT-defined Subclinical TB lesions and their prediction of future TB progression II

2025-09-06 | GSE242685 | GEO

RNA-seq of human blood samples from HIV-infected and HIV-uninfected TB contacts

Project description:RNA-sequencing was performed on baseline blood samples from HIV-infected and HIV-uninfected asymptomatic adults with recent household exposure to an index case of infectious pulmonary tuberculosis (TB) and with detectable Mtb DNA in PBMC. Additional sequencing was also performed on follow-up blood samples from HIV-infected participants following completion of isoniazid preventative therapy.

2025-01-05 | E-MTAB-13672 | biostudies-arrayexpress

Immunopeptidomics reveals determinants of Mycobacterium tuberculosis antigen presentation on MHC class I (DDA data)

Project description:Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), is a leading cause of infectious disease mortality worldwide for which no sufficiently protective vaccine exists. CD8+ T cells contribute to protective immunity to TB, but the antigenic targets presented on MHC-I by macrophages infected with virulent Mtb for recognition by CD8+ T cells have not been conclusively defined. Here, we use mass spectrometry to directly identify Mtb-derived peptides presented on MHC class I (MHC-I) by infected primary human monocyte-derived macrophages. We identified 16 MHC-I peptides derived from 12 Mtb proteins, and validated these identifications using internal standard parallel reaction monitoring (SureQuant). Our results show that this set of antigens is highly enriched for substrates of type VII secretion systems (T7SS) relative to the Mtb proteome. Our results identify specific Mtb proteins that may be suitable targets for subunit vaccines designed to elicit protective CD8+ T cell-mediated immunity and suggest that T7SS substrates may be a fruitful class of antigens to prioritize for further vaccine target discovery efforts. Note: donors labeled A, C, D, E, H, and I in file names here are renamed sequentially (A, B, C, D, E, and F) in the manuscript describing this study to avoid confusion.

2023-04-24 | PXD037837 | Pride

Gene expression profiling identifies a gene signature that predicts progression to active tuberculosis several years before disease onset

Project description:We evaluated the predictive ability of various gene signatures in baseline peripheral blood mononuclear cell samples to distinguish Mtb-infected individuals who eventually progress to TB disease (progressors) or who remain asymptomatic (non-progressors) during clinical follow-up; we also compare long-term Mtb-infected non-progressors from patients with TB disease

2020-02-25 | GSE112104 | GEO

INTEGRATIVE MULTI-OMICS REVEAL A TWO-ANALYTE BLOOD-BASED SIGNATURE FOR TB DIAGNOSIS IN ADVANCED HIV

Project description:Tuberculosis (TB) accounts for disproportionate morbidity and mortality among persons living with HIV (PLWH). Conventional methods of TB diagnosis, including smear microscopy and Xpert MTB/RIF, have lower sensitivity in PLWH. Novel high-throughput approaches, such as miRNAomics and metabolomics, may advance our ability to diagnose subclinical and difficult to diagnose TB, especially in very advanced HIV. We conducted a case-control study leveraging REMEMBER, a multi-country, open-label randomized controlled trial comparing 4-drug empiric standard TB treatment with isoniazid preventive therapy in PLWH initiating ART with CD4 cell counts <50 cells/uL. Twenty-three cases of incident TB were site-matched with 32 controls to identify miRNAs, cytokines/chemokines, and metabolites associated with the development of newly diagnosed TB in PLWH. Differentially expressed miRNA analysis revealed 11 altered miRNAs with a fold change higher than ±1.4 in cases relative to controls (p<0.05). Differentially altered metabolite analysis showed no significant alterations in metabolites between cases and controls. We found higher TNFα and IP-10/CXCL10 in cases (p=0.011, p=0.0005), and higher MDC/CCL22 in controls (p=0.0072). A decision tree algorithm identified gamma-glutamylthreonine and hsa-miR-215-5p as the optimal variables to classify incident TB cases (AUC 0.965). hsa-miR-215-5p, which targets genes in the TGF-β signaling pathway, was downregulated in cases. Gamma-glutamylthreonine, a breakdown product of protein catabolism, was less abundant in cases. To our knowledge, this is one of the first uses of a multi-omics approach to identify incident TB in a severely immunosuppressed PLWH study.

2021-06-30 | GSE166557 | GEO

Protein composition of circulating exosomes depend on tuberculosis disease state

Project description:Tuberculosis (TB) is a contagious disease that is a primary cause of mortality and illness in around a quater of the world' population particular in low income nations. The disease most commonly affects lung, but pathogens can also be found in other parts of the body. Mycobacterium tuberculosis (Mtb) is the etiologic agent of TB and its ability to penetrate immune cells and develop a niche by beating the host's defense mechanism is crucial to its pathogenic sucess. Mtb has a diverse lipid and protein spectrum. Understanding the host-pathogen-interplay in active TB will have a substantial impact in understanding molecular mechanisms of Mtb infection and guide the development of vaccination, diagnostics and therapy response monitoring.

2022-05-20 | PXD030883 | Pride

Whole Genome Sequence Analysis of Mycobacterium tuberculosis Strains from Patients in Campania Region

Project description:Tuberculosis (TB) is one of the deadliest infectious disorders in the world. To effectively TB manage, an essential step is to gain insight into the lineage of Mycobacterium tuberculosis (MTB) strains and the distribution of drug resistance. Although the Campania region is declared a cluster area for the infection, to contribute to the effort to understand TB evolution and transmission, still poorly known, we have generated a dataset of 159 genomes of MTB strains, from Campania region collected during 2018-2021, obtained from the analysis of whole genome sequence data. The results show that the most frequent MTB lineage is the 4 according for 129 strains (81.11%). Regarding drug resistance, 139 strains (87.4%) were classified as multi susceptible, while the remaining 20 (12.58%) showed drug resistance. Among the drug-resistance strains, 8 were isoniazid-resistant MTB (HR-MTB), 7 were resistant only to one antibiotic (3 were resistant only to ethambutol and 3 isolate to streptomycin while one isolate showed resistance to fluoroquinolones), 4 multidrug-resistant MTB, while only one was classified as pre-extensively drug-resistant MTB (pre-XDR). This dataset expands the existing available knowledge on drug resistance and evolution of MTB, contributing to further TB-related genomics studies to improve the management of TB infection.

2023-11-17 | E-MTAB-13058 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data